Abstract:Ling Wu, 1, &ast Nan Lan, 2, &ast Xiaoyu Yang 3 1 Department of Respiratory Medicine, The First People's Hospital of Shuangliu District, Chengdu, People's Republic of China; 2 Department of Respiratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China; 3 Department of Respiratory Medicine, Peking University First Hospital, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaoyu Yang Email Background: Clinicians' selection of glucocorticoids during hospitalization of COPD patients is often based on the medical staff's judgment of the patient's condition, and there is no objective judgment standard. The purpose of this study was to investigate the outcome of severe COPD deterioration in patients treated with glucocorticoid and without glucocorticoid during hospitalization. Methods: This study was an observational cohort study. Data on hospitalization with severe COPD deterioration were collected and followed up for 1 year. One year after discharge, the re-hospitalization due to COPD was collected retrospectively. The patients were divided into glucocorticoid group and control group according to whether the patients were given glucocorticoid therapy or not when they were admitted to hospital for the first time. The primary outcome was rate of future COPD exacerbations, while the secondary outcome was hospital stay, treatment cost and COPD-related readmission time. These results are analyzed by using Poisson model and Cox regression model. Results: A total of 91 patients were enrolled in the study, including 39 in the control group and 52 in the glucocorticoid group. The annual rate of future COPD exacerbations in the glucocorticoid group was significantly lower than that in the control group (RR,0.50 [95% CI, 0.26– 0.98]; P = 0.045). The risk of COPD recurrence in the glucocorticoid group was lower than that in the control group, as assessed in a time-to-first-event analysis (HR,0.46[95% CI 0.22– 0.97]; P = 0.042). Subgroup analysis found that in patients with blood eosinophil < 100 cells/μ l, the future annual severe exacerbation rate of glucocorticoid group was significantly lower than that in the control group (adjusted RR,0.37 [95% CI 0.17– 0.83]; P = 0.016). Conclusion: The use of glucocorticoids during hospitalization in COPD can more effectively reduce the severe deterioration of COPD than without glucocorticoids. Keywords: COPD, glucocorticoid, exacerbation Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by persistent airflow limitation. The primary clinical symptoms are cough, expectoration and dyspnea, and the morbidity and mortality are gradually increasing. The latest research by Wang et al shows that in China, the overall prevalence rate of COPD is 8.6%. The prevalence rate of COPD in people over 40 years old is 13.7%. 1 About 25 million people worldwide die of chronic obstructive pulmonary disease (COPD) every year. 2 COPD ranks fourth in the cause of death in the world and seventh in the burden of disease. 3,4 Acute exacerbation of COPD refers to the aggravation of respiratory symptoms, the degree of change is beyond the range of daily variation and leads to changes in drug treatment. The therapeutic drugs for COPD primary include bronchodilators, glucocorticoids, antibiotics, expectorants and so on. In stable COPD patients with FEV1 < 60% predicted, regular inhalation of glucocorticoids can improve symptoms, lung function, improve quality of life and reduce the frequency of acute exacerbation. Clinical studies have also shown that glucocorticoid use in AECOPD patients can shorten recovery time, improve pulmonary function and hypoxemia, and reduce the risk of recurrence and treatment failure, 5 but may lead to an increased risk of pneumonia and fungal infection. 6 Therefore, the clinical benefits and risks of patients with COPD need to be fully considered in both acute exacerbation and stable phase. The number of eosinophils has been used as the only biological indicator of long-term inhalation of sex glucocorticoids in stable COPD, but at present, there is no unified standard in the guidelines for the selection of glucocorticoid therapy in patients with AECOPD, so the clinical selection is quite different, and the long-term effect is not exact. 7 Medical staff often make empirical judgment on the glucocorticoid selection of patients with AECOPD based on the judgment of patients' symptoms. Therefore, this study investigated the indicators and prognosis of patients with severe COPD deterioration trea -Abstract Truncated-

Effect and its clinical significance of different dose of glucocorticoids on inflammation mediators in patients with acute exacerbation of chronic obstructive pulmonary diseases

Efficacy and Safety of Glucocorticoids in Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Application of short-term glucocorticoid therapy in acute exacerbation of chronic obstructive pulmonary disease

[The Effects and Therapeutic Duration of Oral Corticosteroids in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Diseases].

Evaluating the Efficacy and Side Effects of Corticosteroid Therapy in Severely ill COVID-19 Patients

Effects of and Smeton on inflammatory mediator levels and therapeutic outcomes in elderly patients with chronic obstructive pulmonary disease

The IL-8,LTB4 Levels and the Pulmonary Function of Patients with Chronic Obstructive Pulmonary Disease Around Hormone Treatment

Effects of Empirical Glucocorticoid Use on Severe Acute Exacerbation of COPD During Hospitalization

The effect of inhaled glucocorticoid aerosol in pulmonary function and serum cortisol for patients with asthma

Efficacy of corticosteroid treatment for severe community-acquired pneumonia: A meta-analysis.

Glucocorticoid Use in Patients Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations

Efficacy And Safety Of Glucocorticoids In The Treatment Of Severe Community-Acquired Pneumonia A Meta-Analysis

Changes of Metailoproteinase-9, Tissue Inhibitor of Metalloproteinase-1 and Interleukin-8 in Elderly Patients with Chronic Obstructive Pulmonary Disease and the Effects of Different Drugs

Effect of Low-to-moderate Dose Glucocorticoids on Viral Clearance in COVID-19: a Retrospective Study

Inhalation of Β_2-Agonist,anticholinergics and Glucocorticosteroid in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Glucocorticoids in the Treatment of Severe Community-Acquired Pneumonia

The Controversy about the Effects of Different Doses of Corticosteroid Treatment on Clinical Outcomes for Acute Respiratory Distress Syndrome Patients: an Observational Study

Evaluation of Corticosteroid Dose in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Current situation and evidence of glucocorticoid therapy for acute exacerbation of chronic obstructive pulmonary disease

A Step‐wise Application of Methylprednisolone Versus Dexamethasone in the Treatment of Acute Exacerbations of COPD

Systemic Corticosteroid Forcopdexacerbations, Whether the Higher Dose is Better? A Meta‐analysis of Randomized Controlled Trials